Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Pharmacology

Background:

• Intraperitoneal (IP) chemotherapy improves survival in advanced ovarian cancer compared to intravenous (IV) chemotherapy.
• However, IP chemotherapy is associated with increased adverse events, toxicities, and administration challenges.
• These challenges include technical difficulties and demanding schedules.

Purpose of the Study:

• To report the initial experience with IP chemotherapy administration in Australia.
• To evaluate the feasibility and practicality of IP chemotherapy in two Australian gynaecological oncology units.

Main Methods:

• Retrospective data collection from 23 women with advanced ovarian cancer receiving adjuvant IP chemotherapy.
• Collection of standard toxicity data (CTCAE v3.0) and IP-specific administration data.

Main Results:

• Patients received an average of 4.3 IP chemotherapy cycles, with 43% completing all six planned cycles.
• 39% of patients discontinued IP treatment due to drug-related toxicities (22%) or administration-related complications (17%).

Conclusions:

• The study demonstrates the feasibility and practicality of IP chemotherapy for ovarian cancer in Australia.
• Key lessons learned from initial experiences are highlighted, informing future practice.